JPMorgan Chase & Co’s ALX Oncology ALXO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $36.7K | Sell |
88,352
-269,605
| -75% | -$112K | ﹤0.01% | 5187 |
|
|
2025
Q1 | $223K | Buy |
357,957
+121,911
| +52% | +$76K | ﹤0.01% | 4398 |
|
|
2024
Q4 | $394K | Buy |
236,046
+195,112
| +477% | +$326K | ﹤0.01% | 4250 |
|
|
2024
Q3 | $74.5K | Buy |
40,934
+509
| +1% | +$926 | ﹤0.01% | 4841 |
|
|
2024
Q2 | $244K | Sell |
40,425
-1,472
| -4% | -$8.88K | ﹤0.01% | 4184 |
|
|
2024
Q1 | $467K | Sell |
41,897
-5,686
| -12% | -$63.4K | ﹤0.01% | 4000 |
|
|
2023
Q4 | $709K | Buy |
47,583
+25,848
| +119% | +$385K | ﹤0.01% | 3715 |
|
|
2023
Q3 | $104K | Buy |
21,735
+3,179
| +17% | +$15.3K | ﹤0.01% | 4580 |
|
|
2023
Q2 | $139K | Buy |
18,556
+749
| +4% | +$5.63K | ﹤0.01% | 4474 |
|
|
2023
Q1 | $81K | Buy |
17,807
+4,391
| +33% | +$20K | ﹤0.01% | 4732 |
|
|
2022
Q4 | $151K | Sell |
13,416
-1,165
| -8% | -$13.1K | ﹤0.01% | 4332 |
|
|
2022
Q3 | $140K | Buy |
14,581
+1,153
| +9% | +$11.1K | ﹤0.01% | 4324 |
|
|
2022
Q2 | $109K | Sell |
13,428
-5,809
| -30% | -$47.2K | ﹤0.01% | 4587 |
|
|
2022
Q1 | $326K | Buy |
19,237
+3,417
| +22% | +$57.9K | ﹤0.01% | 4212 |
|
|
2021
Q4 | $340K | Buy |
15,820
+792
| +5% | +$17K | ﹤0.01% | 4263 |
|
|
2021
Q3 | $1.11M | Buy |
15,028
+2,683
| +22% | +$198K | ﹤0.01% | 3543 |
|
|
2021
Q2 | $675K | Buy |
12,345
+2,413
| +24% | +$132K | ﹤0.01% | 3837 |
|
|
2021
Q1 | $732K | Buy |
9,932
+4,838
| +95% | +$357K | ﹤0.01% | 3832 |
|
|
2020
Q4 | $439K | Buy |
5,094
+1,526
| +43% | +$132K | ﹤0.01% | 3814 |
|
|
2020
Q3 | $137K | Buy |
+3,568
| New | +$137K | ﹤0.01% | 3921 |
|